Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s

Theodoros Kelesidis, Carlee Moser, James H. Stein, Todd T. Brown, Thuy Tien T. Tran, Heather J. Ribaudo, Michael P. Dube, Otto O. Yang, Judith S. Currier, Grace A. McComsey

Research output: Contribution to journalArticlepeer-review

Abstract

It is unclear whether differential roles of CD4<>+< versus CD8+ T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4<>+< T-cell senescence (ie, the percentage of CD28?CD57+ cells among CD4<>+< T cells ) and CD4<>+</CD8+ T-cell exhaustion (ie, the percentage of PD-1+ cells among CD4<>+</CD8+ T cells) decreased after ART. There were no changes inmarkers of CD8+ T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4<>+< and CD8+ T cells may have differential roles in HIV pathogenesis.

Original languageEnglish (US)
Pages (from-to)748-752
Number of pages5
JournalJournal of Infectious Diseases
Volume214
Issue number5
DOIs
StatePublished - Sep 1 2016

Keywords

  • Antiretroviral therapy
  • Biomarkers
  • Human immunodeficiency virus
  • Immune activation
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s'. Together they form a unique fingerprint.

Cite this